Competitor comparison (Bullish insight)

Fibromyalgia market is $2.7B and expected $4.13B by end of 2032.

The drug's only competitor [Lyrica] made $200M its first year on the market in 2005, which translates to $330M today, factoring inflation.

Fibro market was $1.5B in 2005, it nearly doubled to $2.7B today.

Furthermore, Lyrica made $2B in 2021, $1.6B in 2022, $900M in 2023, and $1B in 2024.

Since Lyrica debut sales were $330M within a $1.5B fibro market, Tonix will generate at least $300M+ with a $2.7B fibro market. And that's being very conservative.

Even on the absolute low end, that's still a market cap of $1B+ when factoring the market/sector P/S ratio average 3x-5x.

If TNX-102 is approved, this stock will 10X in value, probably more.

Thoughts?